The FDA announced today that it has approved Opdivo (nivolumab) for use in NSCLC patients who have progressed on or after platinum-based chemotherapy.
The FDA today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses and 159,260 deaths in 2014. The most common type of lung cancer, NSCLC affects seven out of eight lung cancer patients, occurring when cancer forms in the cells of the lung.
Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells. Opdivo is intended for patients who have previously been treated with platinum-based chemotherapy.
Link to the FDA apporval notice: http://1.usa.gov/1AKf5nR
Link to the BMS press release: http://bit.ly/1aLOy4Q